Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Thromb Haemost ; 114(4): 778-92, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26272227

RESUMO

The relative efficacy and safety of dabigatran etexilate and warfarin have been evaluated in two head-to-head, phase III, treatment of acute venous thromboembolism (VTE) trials, and one extended prophylaxis trial, in patients with high risk of recurrent VTE. Dabigatran etexilate demonstrated similar efficacy to warfarin, and was associated with a reduced risk of major or clinically relevant bleeds. Based on results of these trials, and real-life disease prognosis following discontinuation of anticoagulation treatment, we evaluated the cost-utility of dabigatran etexilate compared with warfarin in six months anticoagulation, and in extended, up to 24 months anticoagulation, in patients with acute VTE, acute deep-vein thrombosis (DVT) or acute, symptomatic, pulmonary embolism (PE). Costs were analysed from the perspective of the National Health Services (NHS) and Public Social Services (PSS) in England and Wales. Outcomes were quantified in quality-adjusted life years (QALY). The estimated incremental, lifetime cost/QALY gain following acute, symptomatic VTE (DVT or PE) was £1,252/QALY when dabigatran etexilate or warfarin were administered for up to six months treatment. In treatment of acute, symptomatic PE and in DVT respective ratios were £1,767/QALY and £1,075/QALY. In extended, up to 24 months anticoagulation, dabigatran etexilate projected costs/QALY of £8,242/QALY, when compared with warfarin. Results obtained herein were robust across a number of sensitivity analyses and suggest dabigatran etexilate to be a cost-effective alternative to current standard of care when evaluated in six months treatment and in extended anticoagulation following acute VTE (DVT and/or PE).


Assuntos
Anticoagulantes/economia , Anticoagulantes/uso terapêutico , Dabigatrana/economia , Dabigatrana/uso terapêutico , Custos de Medicamentos , Embolia Pulmonar/tratamento farmacológico , Embolia Pulmonar/economia , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/economia , Trombose Venosa/tratamento farmacológico , Trombose Venosa/economia , Varfarina/economia , Varfarina/uso terapêutico , Doença Aguda , Anticoagulantes/efeitos adversos , Análise Custo-Benefício , Dabigatrana/efeitos adversos , Esquema de Medicação , Hemorragia/induzido quimicamente , Hemorragia/economia , Humanos , Estimativa de Kaplan-Meier , Modelos Econômicos , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/mortalidade , Anos de Vida Ajustados por Qualidade de Vida , Medicina Estatal/economia , Fatores de Tempo , Resultado do Tratamento , Reino Unido , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/mortalidade , Trombose Venosa/diagnóstico , Trombose Venosa/mortalidade , Varfarina/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA